DDX3X induces mesenchymal transition of endothelial cells by disrupting BMPR2 signaling
FEBS Open Bio · 2025
DOI: 10.1002/2211-5463.70155 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEBS Open Bio, 2025. Verfasst von Yu Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing, China. Hauptthemen laut MEDLINE: DEAD-box RNA Helicases, Bone Morphogenetic Protein Receptors, Type II, Endothelial Cells, Epithelial-Mesenchymal Transition. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Chongqing Municipality, National Natural Science Foundation of China, National Natural Science Foundation of China-Guangdong Joint Fund.
Abstract (Originalsprache)
Endothelial‐to‐mesenchymal transition (EndoMT), a widely recognized biological process leading to abnormal endothelial function, has been implicated in various cardiovascular pathologies. DEAD‐box proteins represent the largest family of RNA helicases associated with multiple physiological and pathophysiological processes; however, their role in the homeostasis of endothelial cells (ECs) remains largely unexplored. Here, we show that the levels of DEAD‐box protein 3 X‐linked (DDX3X), a DEAD‐box RNA helicase protein, were significantly increased during EC transition in vivo and in vitro . DDX3X overexpression promoted EndoMT as well as endothelial dysfunction and inflammation, whereas its downregulation effectively inhibited this transition in ECs. Mechanistically, elevated DDX3X resulted in downregulation of bone morphogenetic protein receptor type 2 (BMPR2), a protein that is pivotal for maintaining endothelial homeostasis and function. Furthermore, our co‐immunoprecipitation assays demonstrated a molecular interplay between DDX3X and BMPR2. Importantly, DDX3X was shown to promote the lysosomal degradation of BMPR2, thereby interrupting its downstream signal transduction. These findings identify DDX3X as a novel regulator of EndoMT by modulating BMPR2 signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Disease, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
- Department of Cardiology, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
- Department of Pathology, Xinqiao Hospital, Third Military Medical University, Chongqing, China.
- Department of Intensive Medicine, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu, China.
ORCID-Profile: Ye Fan
Förderung
- Natural Science Foundation of Chongqing Municipality
- National Natural Science Foundation of China
- National Natural Science Foundation of China-Guangdong Joint Fund
Zitieren
APA
Zhang, Y., Wang, J., Qian, D. H., Lv, Y. F., Cheng, T. L., Wang, D. P., Zhang, J., & Fan, Y. (2025). DDX3X induces mesenchymal transition of endothelial cells by disrupting BMPR2 signaling. FEBS Open Bio. https://doi.org/10.1002/2211-5463.70155
Vancouver
Zhang Y, Wang J, Qian DH, Lv YF, Cheng TL, Wang DP, et al. DDX3X induces mesenchymal transition of endothelial cells by disrupting BMPR2 signaling. FEBS Open Bio. 2025. doi:10.1002/2211-5463.70155
BibTeX
@article{Zhang2025,
author = {Zhang, Yu and Wang, Jing and Qian, De-Hui and Lv, Yang-Fan and Cheng, Tian-Le and Wang, Da-Peng and Zhang, Jing and Fan, Ye},
title = {DDX3X induces mesenchymal transition of endothelial cells by disrupting BMPR2 signaling},
journal = {FEBS Open Bio},
year = {2025},
doi = {10.1002/2211-5463.70155}
}
EUVIMED